Eckert & Ziegler’s GalliaPharm®, exclusively distributed by Jubilant Radiopharma, approved for use with NETSPOT in Canada
Eckert & Ziegler’s GalliaPharm®, exclusively distributed by Jubilant Radiopharma, approved for use with NETSPOT in Canada
Berlin, Germany and Yardley, PA – September 22, 2021: On June 30, 2021 Health Canada approved Eckert & Ziegler Radiopharma’s GalliaPharm® Ge68/Ga-68 generator for use with Advance Accelerator Systems’ NETSpot kit used for the localization of somatostatin receptor positive neuroendocrine tumors (NET) in adult patients using Positron Emission Tomography (PET).
“NETSPOT® is the only registered Ga-68 based radiopharmaceutical in Canada”, explained Dr. Harald Hasselmann, Eckert & Ziegler Executive Director and responsible for the Medical segment. “Therefore, after the successful approval of GalliaPharm® by Health Canada in 2020, this marks another important milestone for making such diagnostics broadly available to nuclear medicine practices and clinics in Canada together with our partners from Jubilant Radiopharma™.”
“As the exclusive distribution partner of the GalliaPharm® generator in Canada, we are very pleased to provide state-of-the-art diagnostic services to more Canadian patients suffering from cancer, while also helping healthcare professionals realize the value of new and novel nuclear medicine products”, stated Sergio Calvo, President of Jubilant’s Radiopharmaceuticals Division.
GalliaPharm® is available with the following activities: 740 MBq, 1110 MBq, 1480 MBq and 1850 MBq (20 mCi, 30 mCi, 40 mCi, 50 mCi). It is registered as a medicinal product in 17 European countries and Canada. Eckert & Ziegler Radiopharma GmbH is also a holder of a Type II Drug Master File (#28741) in the USA.
According to CNETS, with approximately 12,000 – 15,0001 Canadians living with NETs, this form of cancer has gone from being once rare to one of the fastest-growing classes of cancer worldwide.
1CNETS - Canadian Neuroendocrine Tumor Society